Medicare Launched GLP-1 Coverage. Your Employer Probably Still Won't Cover It.

Medicare opened GLP-1 coverage for obesity on July 1, 2026. Wegovy, Zepbound, and Foundayo are now $50 a month for eligible seniors. Novo Nordisk has been cutting cash prices to keep pace with Eli Lilly. Analysts expected employer plans to follow.

They did not.

A survey from the International Foundation of Employee Benefit Plans, released July 8, 2026, found that 36% of US employers cover GLP-1s for both diabetes and weight loss. That is the same 36% as 2025. 60% cover GLP-1s for diabetes only. 3% do not cover them at all. 2% are not sure.

At the same time, GoodRx data shows over 114 million Americans have no insurance coverage for Zepbound. That is up 17 million people from 2025. 88% of the people who do have coverage face prior authorization or other restrictions.

This piece walks through why employer coverage held flat, what employers are doing instead, and what it means for someone who wants a GLP-1 for weight loss.

The International Foundation of Employee Benefit Plans (IFEBP) runs a yearly Pulse Survey of employers to ask how they cover GLP-1 drugs. The 2026 survey ran June 2 to June 12, right before the Medicare Bridge launched.

Here is the full breakdown of the 2026 results:

• 60% of employers cover GLP-1s for diabetes only. This has been the largest group for years, since Ozempic and Mounjaro are FDA-approved for type 2 diabetes.
• 36% cover GLP-1s for both diabetes and weight loss. This share was 34% in 2024, 36% in 2025, and 36% in 2026. Basically flat.
• 3% do not cover GLP-1s at all.
• 2% are not sure what their plan does.

Mercer, the benefits consulting firm, ran a parallel survey with similar results. So did the Business Group on Health.

The pattern is clear: employers that were going to cover GLP-1s for weight loss already do. Employers that have not added the coverage are not adding it now, even with Medicare moving. The line has held for two years in a row.

There is one statistic that explains most of the story. Among employers that cover GLP-1s for weight loss, GLP-1 drugs made up 11.4% of total prescription-drug claims in 2026. That is up from 10.5% in 2024 and 6.9% in 2023.

Think about what that means. Every other prescription drug a company pays for (blood pressure medicines, mental-health medicines, cancer drugs, everything) fits into the other 88.6% of the claims budget. GLP-1s for weight loss alone eat 11 cents of every dollar the plan spends on drugs.

Employers are self-insured. When your employer 'covers' a drug, they are literally paying the pharmacy claim (minus your copay) out of the company's health-benefits budget. The 11.4% share comes straight from that budget.

A covered GLP-1 patient costs a self-insured employer roughly $500 to $700 per month even after rebates. Multiply that by 5% to 10% of an employee population that would qualify, and the total bill runs into the millions of dollars per year for a mid-sized company.

Most employers reviewed those numbers in 2024 and 2025 and made a decision. The employers who decided yes are the 36% already covering. The employers who decided no did not change their answer this summer.

GoodRx tracks insurance coverage for weight-loss drugs across US commercial health plans. As of July 2026, more than 114 million Americans have no insurance coverage at all for Zepbound (tirzepatide). That is up 17 million from 2025.

The coverage change is about more than employer choices. It also reflects how existing plans have tightened their rules mid-year.

For Zepbound in 2026:

• Unrestricted coverage fell from 5% of the covered population to 4%
• Restricted coverage (usually meaning prior authorization or step-therapy requirements) fell from 45% to 37%
• No coverage rose sharply

For Wegovy (semaglutide):

• Unrestricted coverage fell from 10% to 9%
• Restricted coverage rose slightly from 75% to 77%

Across both drugs, 12 million people lost some form of Zepbound coverage between 2025 and 2026, and 12 million lost some form of Wegovy coverage.

For the people who still have coverage, 88% face additional requirements before the pharmacy will fill the prescription. That usually means the doctor has to send in paperwork proving the patient meets specific BMI and comorbidity criteria, and often has to document that the patient tried other weight-loss approaches first.

Employers not expanding coverage found ways to help without adding the drugs to the plan.

About 27% of employers now steer workers toward direct-to-consumer cash-pay platforms for GLP-1s. That means the employer does not cover the drug and instead points employees to a channel where they can pay themselves.

The two big cash channels are LillyDirect and NovoCare Pharmacy. LillyDirect sells Zepbound single-dose vials starting at $349 for the 2.5 mg dose (28-day supply), going up to $499 for higher doses. NovoCare sells Wegovy for as low as $199 for the first two months of the 0.25 mg starter dose, then $499 per month.

About 21% of employers push workers to use pre-tax dollars from a Flexible Spending Account (FSA), Health Savings Account (HSA), or Health Reimbursement Arrangement (HRA). The employer does not pay for the drug; the employee gets to pay with tax-advantaged dollars, which is roughly a 25-30% discount depending on the tax bracket.

Some employers combine both moves: they steer workers to LillyDirect or NovoCare and tell them to pay with HSA money. That gives the employee the lowest available cash price with a tax advantage, without adding the drug to the plan.

A smaller share of employers (roughly 10-15%) offers a wellness program, coaching, or lifestyle intervention as a prerequisite before covering the drug. The idea is that if the employee is going to be on a GLP-1 for years, the employer wants some diet and exercise support built in first.

The Medicare GLP-1 Bridge launched July 1, 2026, for eligible Part D beneficiaries. It sets copays at $50 per month for Wegovy, Zepbound KwikPen, and Foundayo through December 31, 2027. The federal government pays roughly $195 per month per beneficiary net of the $50 copay.

The program is a demonstration, not a permanent coverage decision. It runs for 18 months, then transitions into the BALANCE Model, which is a broader Medicare coverage redesign for weight-related conditions.

Employer plans do not typically follow Medicare demonstrations for two reasons.

First, Medicare is negotiating a specific net price with manufacturers as part of the Bridge (approximately $245 per month). Employer plans do not have access to that price. Their pharmacy benefit managers negotiate separate rebates, and the net cost to a self-insured employer for a covered GLP-1 patient runs closer to $500 to $700 per month after all rebates. The Medicare price is not the employer price.

Second, Medicare demonstrations often end. Employer plans typically wait to see whether a demonstration converts into permanent Medicare coverage before restructuring their own benefits. The BALANCE Model transition is scheduled for late 2027 or early 2028. Employers are watching but not moving.

The practical effect is that Medicare Bridge and employer plans operate on different tracks. A 66-year-old Medicare Part D beneficiary can get Wegovy for $50 per month starting July 1. A 55-year-old employed person at a company that does not cover GLP-1s for weight loss still pays $349 to $499 per month through LillyDirect or NovoCare.

Even for the 36% of employees whose plans do cover GLP-1s for weight loss, actually filling a prescription is harder than it sounds. 88% of covered patients face prior authorization or step therapy requirements.

Prior authorization typically means the doctor has to send the insurance company a set of documents proving that the patient qualifies. The specific criteria vary by plan, but most require:

• A BMI of 30 or higher (or 27 or higher with at least one weight-related comorbidity like type 2 diabetes, high blood pressure, or sleep apnea)
• Documentation of prior attempts at weight loss through diet and exercise (some plans require 6 months of documented lifestyle change)
• A treatment plan showing the doctor is committed to monitoring the patient over time

Step therapy is a related requirement. It means the plan wants the patient to try a cheaper drug first before covering the more expensive one. For GLP-1s, step therapy usually means trying phentermine, Contrave, or Qsymia before Zepbound or Wegovy.

The practical effect is that many patients whose plans technically cover GLP-1s cannot actually start one within the first month. The prior-authorization paperwork usually takes 1-4 weeks for approval, and about 30% of first-time submissions get denied and require an appeal. Some plans limit approval to 6-month cycles, which means the patient goes through the paperwork twice a year to stay on the drug.

Your situation depends on how you got the drug in the first place.

If your employer plan covers GLP-1s for weight loss and you have already met the prior-authorization requirements, your position is stable for now. The 36% employer share is holding. Coverage renewals happen at plan-year boundaries (usually January 1 or the first of your employer's fiscal year), and you may face renewed paperwork at that point. Make sure your doctor is documenting the visits and any weight or health improvements. Plans reviewing coverage look at whether the patient is meeting weight-loss milestones (usually 5% weight loss at 12 months) before renewing authorization.

If your employer does not cover GLP-1s for weight loss and you are paying cash through LillyDirect or NovoCare, that channel is likely to stay open. Both manufacturers have committed to direct-to-consumer cash channels because they are one of the fastest-growing revenue streams. Use HSA or FSA dollars if you have them.

If you lost coverage between 2025 and 2026 and your prescription is running out, you have three paths. First, check whether your doctor can requalify you under updated coverage criteria (some plans loosened diabetes-adjacent criteria mid-year). Second, price out LillyDirect or NovoCare cash-pay for continuation. Third, if you are 65 or older, check Medicare Bridge eligibility (BMI 30+ or BMI 27+ with prediabetes or cardiovascular disease). Many people newly eligible for Medicare Bridge do not know it applies to them.

Do not stop the drug abruptly to save money. Studies show most patients regain weight within 12 months of stopping GLP-1s. If cost is the issue, work with your doctor on the lowest effective dose or a cheaper alternative before ending treatment.

Starting a GLP-1 in 2026 requires more shopping around than it used to.

First, check whether your employer plan covers GLP-1s for weight loss. Look at the summary of benefits or call the pharmacy benefit help line. If the answer is yes, ask about prior authorization requirements. Many employees do not know their plan requires a 6-month documented lifestyle intervention before approving the drug.

Second, if the plan does not cover, ask whether your employer participates in a direct-to-consumer program with LillyDirect, NovoCare, or a third-party platform. Some employers have negotiated preferred pricing that beats the standard cash rate.

Third, price out the cash channels. LillyDirect and NovoCare are the largest, but pharmacy discount card networks (GoodRx) and telehealth providers (Hims, Ro) sometimes offer alternative pricing. Some pharmacies (Costco is one example) fill prescriptions at close to the manufacturer cash price for members.

Fourth, ask about HSA/FSA eligibility. GLP-1s prescribed for weight management are FSA and HSA eligible if the patient has documented obesity or a related comorbidity. That gives you a 25-30% effective discount on out-of-pocket cost.

Fifth, if you are eligible for Medicare, ask your Part D plan about Medicare GLP-1 Bridge enrollment. The program requires a physician prior-authorization submission to Humana (the central processor). Approval typically takes 3-5 business days.

Starting cost matters, but so does one-year cost. GLP-1 dose usually escalates over the first 4-6 months, so the sticker price at month one is not what you will pay at month six. Ask the pharmacy or manufacturer program what full-dose pricing looks like before you commit.

Three developments over the next 24 months could shift employer coverage.

First, generic tirzepatide. Sandoz filed two Abbreviated New Drug Applications with the FDA on June 29, 2026 for generic Mounjaro and generic Zepbound. Eli Lilly's core tirzepatide patents do not expire in the US until 2036, so Sandoz would need to win a patent challenge or wait a decade. But the ANDA filing signals that generic competition is coming. If generic tirzepatide arrives at any point in the next 5 years, the average price could drop 50-70%, which would change the employer coverage math.

Second, retatrutide approval. Eli Lilly's triple agonist retatrutide is in Phase 3 development with topline data expected through late 2026 and 2027. If it gets approved, it will likely launch at premium branded pricing, but its higher efficacy (28.3% weight loss at 48 weeks in TRIUMPH-1 compared to about 22% for tirzepatide and 15% for semaglutide) could shift the value calculation for employers.

Third, Medicare Bridge outcomes. The Bridge runs through December 2027 with formal outcome reporting to CMS. If it shows substantial population-level cost savings (fewer heart attacks, fewer diabetes complications, fewer hospitalizations) that offset the drug cost, employer plans may reconsider. The Bridge is both a coverage program and a demonstration that will produce evidence.

None of the three developments will move employer coverage in the next six months. What they can do is give benefits committees a reason to revisit the coverage decision in the 2027 or 2028 plan year. Until then, the 36% is likely to hold.